Therefore, despite the unclear effects of RAAS inhibitors on ACE2 levels, on susceptibility for SARS-CoV-2 infection, and on COVID-19 severity, RAAS inhibitors should be continued in COVID-19 patients or those at risk of it [142]. Here, ACE2 is linked to COVID-19.